ALNYLAM PHARMACEUTICALS, INC. Material Contracts
Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.
- 2026-04-30: Form 10-Q; Exhibit 10.1; Description Form of Special PSU Award Agreement for Chief Executive Officer..
- 2026-02-12: Form 10-K; Exhibit 10.8; Description Second Amended and Restated 2018 Stock Incentive Plan.
- 2025-10-30: Form 10-Q; Exhibit 10.2; Description Amendment No. 1 to Collaboration and License Agreement by and between the Registrant and F. Hoffmann-La Roche Ltd. and Genentech, Inc. dated September 5, 2025.
- 2025-10-03: Form 8-K; Exhibit 10.1; Description Credit Agreement, dated September 30, 2025, among Alnylam Pharmaceuticals, Inc., the lenders party thereto, Bank of America, N.A., as Administrative Agent, and the other parties named therein..
| Filed | Form | Exhibit | Description |
|---|
| 2026-04-30 | 10-Q | 10.1 | Form of Special PSU Award Agreement for Chief Executive Officer. |
|---|
| 2026-02-12 | 10-K | 10.8 | Second Amended and Restated 2018 Stock Incentive Plan |
|---|